For instance, a prospective analysis of 2,055 community populations discovered that women with lower levels of the typical bone-derived cytokine osteocalcin had a higher risk of nonalcoholic fatty liver disease, and further animal studies revealed that osteocalcin therapy for mice reduced hepatic steatosis (77). Here, BGLAP is linked to metabolic dysfunction-associated steatotic liver disease.